The clinical efficacy of Tirelizol on the treatment of advanced liver cancer and its influence on peripheral PRMT5 and PIVKA-II levels

Abstract

Abstract: Objective To investigate the effects of Tirelizol on protein arginine methyltransferase-5(PRMT5) and PIVKA-II levels and the prognosis of patients with advanced liver cancer.Methods Sixty-eight patients with advanced liver cancer were selected as research objects. They were randomly divided into an observation group and a control group. The control group was treated with Trans-arterial chemo-embolization (TACE), and the observation group was treated with tirellizumab. The levels of liver function paremeters such as alanine aminotransferase (ALT), albumin (ALB), total bilirubin (TBIL), T lymphocytes (CD3⁺, CD4⁺, CD8⁺, CD4⁺/CD8⁺), angiogenic factors including acidic and basic fibroblast growth factors (bFGF, aFGF) and vascular endothelial growth factor (VEGF), and the level of PRMT5 mRNA were compared between the two groups before and after treatment. The vitamin K absence or antagonist-II (PIVKA-II) level, the Functional Assessment of Cancer Therapy-General (FACT-G) scores, short-term efficacy and long-term prognosis were also recorded in the two groups.Results After treatment, compared with the control group, ALT, TBil, aFGF, bFGF, VEGF, PRMT5 mRNA, PIVKA-II and FACT-G scores in the observation group were lower, whereas the Alb, CD3⁺, CD4⁺, CD8⁺ and CD4⁺/CD8⁺ levels were higher (P<0.05). In the observation group, the Objective response rate, clinical control rate, cumulative survival time and cumulative survival rate were 47.06%, 76.47%, 20.46 (19.07, 21.84) months and 52.94%, and those of the control group were 20.59%, 52.94%, 18.04 (16.42, 19.65) months and 35.29%, the differences were statistically significant (P<0.05). The incidence of adverse reactions in the observation group and the control group was 23.53% vs 32.35%, respectively, without statistical significance (P>0.05).Conclusion Tirelizol has a good clinical effect on treating advanced liver cancer, and may improve the immune function, angiogenesis, PRMT5 and PIVKA-II levels.

Key words: Tirelizol, Liver cancer, Late stage, Protein arginine methyltransferase, Abnormal prothrombin

YE Hai-hui, JIANG Hua. The clinical efficacy of Tirelizol on the treatment of advanced liver cancer and its influence on peripheral PRMT5 and PIVKA-II levels[J]. Chinese Hepatolgy, 2023, 28(12): 1435-1439.

References

[1] 刘磊, 韩文豪, 陈涛, 等. 晚期肝癌患者血清转化生长因子 β1在肝动脉化疗栓塞术前后变化及对预后的意义[J]. 中国普通外科杂志, 2018, 27(1): 94-100.
[2] 周晓丹,冀国发,刘亚,等.替雷利珠联合白蛋白紫杉醇治疗晚期肺癌的疗效分析及对T细胞亚群的影响[J].现代生物医学进展,2022,22(11):2128-2132.
[3] 吴岑,黄志扬,伍伯聪,等.阿昔替尼联合替雷利珠单抗在一线靶向治疗失败的晚期肾癌患者中的疗效观察[J].中国临床药理学杂志,2021,37(12):1501-1504.
[4] Yang H, Zhao X, Zhao L, et al.PRMT5 competitively bindsto CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma[J].Oncotarget , 2016, 7(44):72131-72147.
[5] 季婷婷,林讷,徐芳,等.PIVKA-Ⅱ在原发性肝癌中的诊断价值[J].肝胆胰外科杂志,2015,27(4):315-317.
[6] 中国抗癌协会PLC专业委员会,中华医学会肝病学分会PLC学组,中国抗癌协会病理专业委员会,等.原发性肝癌规范化病理诊断指南(2015年版).中华肝脏病杂志,2015,23(5) :321-327.
[7] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90,111.
[8] AF Martinez, N Santana, SA Santiago, et al. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to evaluate the severity of side effects of antineoplastic treatments[J]. Actas Dermo-Sifiliográficas, 2020, 112(1):90-92.
[9] 朱兆承,郎庆波,陈喆,等.肝胆肿瘤治疗功能评定量表中文版的考评[J].中西医结合学报,2008,6(4):341-345.
[10] 赵振梁. 甲磺酸阿帕替尼片联合 TACE 方案治疗中晚期肝癌的近期疗效[J]. 临床合理用药,2023,16(11):87-89,95.
[11] Liu sY, Wu YL.Tislelizumab: an investigational anti-PD-1 anti-body for the treatment of advanced non-small cell lung cancer( NSCLC)[J]. Expent Opin Investig Drugs,2020,29 (12):1355-1364.
[12] 孙振层,王睿,蒋晓鸣,等.肾癌根治术后辅助替雷利珠单抗免疫治疗的临床疗效及生存分析[J].中国肿瘤外科杂志,2022,14(5):494-497,520.
[13] 孙国壮,毛海燕,孔桂美,等.蛋白质精氨酸甲基转移酶5在肿瘤中的作用及其临床应用[J].中国肿瘤生物治疗杂志,2018,25(5):533-537.
[14] 赵宗晨,董振芳,鞠瑛,等.血清AFP、AFP/AFP-L3、PIVKA-Ⅱ及GGT联合检测在肝癌中的诊断价值研究[J].国际检验医学杂志,2019,40(6):661-665.

[1]	CHEN Xiu-feng, JIANG Li-ping, SHEN Ling. Analysis of the effect of TACE combined with PMCT in patients with advanced liver cancer [J]. Chinese Hepatolgy, 2023, 28(9): 1068-1071.
[2]	LI Ming, JIANG Zhu-chun, SHI Yong-gang, DONG Shi-liang, HE Zi-huai, PAN Mei-fang. Evaluation of the therapeutic effect of transcatheter hepatic artery chemoembolization combined with large segment three-dimensional conformal radiotherapy on unresectable primary liver cancer [J]. Chinese Hepatolgy, 2023, 28(9): 1079-1083.
[3]	LI Jiao-jiao, ZHAO Yong-chang, WU Jun-xia. The T lymphocyte and NK cell levels in patients with malignant pleural effusion after radical resection of primary hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(8): 924-927.
[4]	WANG Chun-hong, FENG Wei-wei, ZHANG Jing, SI Chen-fei. A clinical study for the therapeutic effect of arotinib on patients with stage III primary liver cancer after interventional therapy [J]. Chinese Hepatolgy, 2023, 28(8): 928-931.
[5]	ZHANG Hai-rong, LI Jin-song, TIAN Xiu-li, HE Xin, JIANG Jue. A novel treatment on small hepatocellular carcinoma adjacent to large vessels by ultrasound assisted precision microwave ablation [J]. Chinese Hepatolgy, 2023, 28(8): 932-934.
[6]	CHEN Yong-ying, PENG Pan, XU Lei-lei. Application of SVM prediction model in judging the degree of pathological differentiation of primary hliver cancerepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(7): 785-788.
[7]	HONG Han, XU Min-hui, JIN Zheng-kang, LI Gao-chao, XU Xiao-yong. The application of hemihepatic blood flow occlusion combined with intermittent Pringle method in the resection of giant liver cancer [J]. Chinese Hepatolgy, 2023, 28(6): 668-672.
[8]	YANG Li-yue, YANG Xiao-liang, YIN Hui-kang. Application of MRI Dual Lava early and late arterial phases combined with portal phase contrast-enhanced scanning in the diagnosis of liver cancer [J]. Chinese Hepatolgy, 2023, 28(6): 673-675.
[9]	XU Zheng-ju, LIU Hui-guo, YAN Yan-yan, YE Qiao-xia, ZHANG Xiao-man, HUANG Jin-fa, LI Yong-fei, WU Jin-piao. Effect of microwave ablation on serum levels of Golgi protein 73 and alpha fetoprotein in patients with primary liver cancer [J]. Chinese Hepatolgy, 2023, 28(5): 554-558.
[10]	ZHU Ye-chen, GENG Cheng-jun, YIN Hui-kang, LI Ya-nan, FENG Quan-ye. The application of three-dimensional reconstruction in the evaluation of vascular system of primary liver cancer before TACE intervention [J]. Chinese Hepatolgy, 2023, 28(5): 559-563.
[11]	MAO Zhen-zhou, LI Fan, ZHANG Zhe-zhe, FENG Yu, DU Bing-jie. Cox regression analysis of the factors affecting the prognosis of liver cancer patients after total caudate lobectomy [J]. Chinese Hepatolgy, 2023, 28(5): 564-567.
[12]	QIN Xiao-ping, ZHANG Jing, AI Ping. The expression of TREM-1, sCD163 and sB7-H3 in patients with primary liver cancer [J]. Chinese Hepatolgy, 2023, 28(4): 461-464.
[13]	LI Hai-xia, WANG Xiu-xiang, GUO Lin, CHAI Mei, LI Yuan-yuan, GAO Ai-hua, SONG Zhao-wei. Effect of microwave ablation combined with DEB-TACE on immune function and prognosis of patients with advanced hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(4): 465-468.
[14]	GUO Dan-dan, ZHANG Ying-hua, GAO Wen-feng, SHENG Shou-peng, ZHANG Yong-hong. Clinical features of primary liver cancer associated with Wilson's disease [J]. Chinese Hepatolgy, 2023, 28(3): 290-292.
[15]	LIU Er-li, LI Bo-qun, HUANG Ying-ting, CUI Hao, WANG Xiao-jun, ZHANG Hong-ying. Cost-effectiveness comparison of four treatment strategies for primary liver cancer [J]. Chinese Hepatolgy, 2023, 28(2): 193-199.